Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 567-575

  Skoura, Evangelia ^a   Rondogianni, Phivi ^a   Alevizaki, Maria ^b   Tzanela, Marinella ^a   Tsagarakis, Stylianos ^c   Piaditis, George ^d   Tolis, George ^e   Datseris, Ioannis E ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c Polikliniki Hospital   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e HIPPOKRATION HOSPITAL   (Greece)

Author keywords

18F fluorodeoxyglucose; Calcitonin; Medullary thyroid cancer; Multiple endocrine neoplasia syndromes; Positron emission tomography

Indexed keywords

CALCITONIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE TUMOR; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; THYROID CANCER;

ADULT; AGED; CALCITONIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77951768869     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283384587     Document Type: Article

References (22)

1. Clarke S. Medullary thyroid cancer. In: A ° ll PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. London: Churchill Livingstone; 2004. pp. 165-174.
2. Dionigi G, Bianchi V, Rovera F, Boni L, Piantanida E, Tanda ML, et al. Medullary thyroid carcinoma: surgical treatment advances. Expert Rev Anticancer Ther 2007; 7:877-885.
3. Schlumberger M, Pacini F. Medullary thyroid carcinoma. In: Schlumberger M, Pacini F, editors. Thyroid tumors. 2nd ed. Paris: Editions Nucleon; 2003. pp. 305-332.
4. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Prac Endocrine Metab 2008; 4:22-32.
5. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565-612.
6. Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of [18F]-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 2008; 34:581-586.
7. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27:490-496.
8. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28:64-71.
9. Iagaru A, Masamed R, Singer P, Conti P. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol 2007; 9:72-77.
10. Szaká ll S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43:66-71.
11. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplasic thyroid carcinomas. Cancer Control 2005; 12:254-260.
12. Diehl M, Risse J, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001; 28:1671-1676. (Pubitemid 33036110)
13. De Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11:786-794.
14. Giraudet AL, Vanel D, Leboulleux S, Aupé rin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185-4190.
15. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of [18F]-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501-507.
16. Bockisch A, Brandt-Mainz K, Görges R, Müller S, Stattaus J, Antoch G. Diagnosis in medullary thyroid cancer with [18F]DG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 2003; 30:22-25.
17. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/ CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:49-57.
18. Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen- targeted radioimmunotherapy. J Clin Endocrinol Metab 2007; 92: 4590-4597.
19. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008; 49:524-531.
20. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33:460-466.
21. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Tognarini I, Luzi E, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006; 1:45.
22. Pestourie C, Thé zé B, Kuhnast B, Le Helleix S, Gombert K, Dollé F, et al. PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L: DOPA. Eur J Nucl Med Mol Imaging 2010; 37:58-66.